◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › P › PHN

Pharmanutra S.p.A. (PHN) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-10-03

Pharmanutra S.p.A. (PHN) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Pisa, Italy with about 144 employees. Its market capitalization is roughly €672 million. In the fiscal year ended 2025-12-31, PHN reported €133M in revenue and €20M in net income.

Pharmanutra S.p.A., a nutraceutical company, engages in the research and development and marketing of food supplements and medical devices in Europe, the Middle East, Far East, North America, South America, and internationally.

Interactive charts & full statements → Open the PHN valuation workbench →

PHN Revenue & Earnings History — Annual Income Statement

Income statement	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total Revenue	€133M	€117M	€101M	€83M	—
Gross Profit	€103M	€91M	€72M	€62M	—
Operating Income (EBIT)	€30M	€28M	€24M	€23M	—
Net Income	€20M	€17M	€13M	€15M	—

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PHN Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31
Total Revenue	€41M	€33M	€37M	€33M	€36M	—
Gross Profit	€31M	€25M	€29M	€25M	€28M	—
Operating Income (EBIT)	€10M	€5M	€8M	€8M	€11M	—
Net Income	€6M	€4M	€6M	€5M	€7M	—

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PHN Free Cash Flow History

Cash flow	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Dividends Paid	(€10M)	(€8M)	(€8M)	(€7M)	—

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PHN Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31
Dividends Paid	—	—	€0M	€0M	—	—

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PHN Balance Sheet History

Balance sheet	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total Assets	€125M	€117M	€112M	€100M	—
Total Liabilities	€54M	€55M	€58M	€49M	—

EUR; €M / €B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive PHN viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

GUD · Knight Therapeutics Inc. — C$1 billion
ESPR · Esperion Therapeutics, Inc. Common Stock — $819 million
0239 · Pak Fah Yeow International Limited — HK$773 million
0950 · Lee's Pharmaceutical Holdings Limited — HK$698 million
3737 · Zhongzhi Pharmaceutical Holdings Limited — HK$637 million
EVT · Evotec SE — €547 million
VIVIMEDLAB · Vivimed Labs Limited — ₹521 million
BIOFILCHEM · Biofil Chemicals and Pharmaceuticals Limited — ₹490 million

← PHM All “P” companies PHO →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.